From Sexual Liberation to Menopausal Freedom - Boomer Women Enter Menopause with Positive Attitudes and Effective Treatments

Actress Meredith Baxter Joins American Medical Women's Association and

Pharmacia Corporation to Reach Out to Women Who Embrace Menopause



Apr 25, 2001, 01:00 ET from Pharmacia Corporation

    NEW YORK, April 25 /PRNewswire/ -- Actress and women's health activist
 Meredith Baxter today joins the American Medical Women's Association (AMWA)
 and Pharmacia Corporation, marketers of the hormone replacement therapy
 ACTIVELLA(TM) (estradiol/norethindrone acetate tablets), to launch the
 Speaking with an Active Voice program.  This nationwide grant program
 recognizes women who celebrate an active and meaningful life as they enter
 menopause.  The program provides seed funding to selected menopausal women who
 are enhancing their lives and the lives of those around them by embarking on
 new undertakings.
     "There are 4,000 baby boomer women entering menopause daily who expect to
 continue leading busy lives.  They aren't and don't want to be slowed down by
 symptoms associated with menopause," says Meredith Baxter, spokesperson for
 the Speaking with an Active Voice program.  "The Speaking with an Active Voice
 program embodies the spirit of ACTIVELLA(TM) by encouraging menopausal women
 to celebrate vibrant and energetic life choices."
     The nationwide program provides grants of at least $6,500 for as many as
 15 women ages 45-55 who are beginning or building upon a work venture, form of
 self-expression or community service. Women have until Monday, July 2, 2001 to
 apply for the grants.  Winners will be notified by Wednesday, August 29, 2001.
 
     This is Not Your Mother's Menopause
     Ensuring that women have the information and tools available to actively
 manage menopause is more important than ever.  Women of menopausal age make up
 the largest segment of the American population, with 41.75 million women over
 the age of 50(1).  Approximately 4,000 women enter menopause each day.  And in
 2000, three out of four (78.2 percent) women between the ages of 45 and 55
 worked outside of the home compared to two out of four (49.9 percent) women in
 1960.
     "Women don't want, and often can't afford, to slow down during menopause,"
 adds Baxter.  "Contraceptives liberated baby boomers during their
 child-bearing years.  Now as these women enter menopause, they expect to enjoy
 this vital time without skipping a beat.  With today's prescription hormone
 replacement therapies (HRTs), such as plant-derived ACTIVELLA(TM), women can
 expect effective relief from moderate to severe hot flashes and night sweats
 often associated with this chapter in their lives."
     "HRTs provide women with options to manage menopausal symptoms and can
 also offer long-term benefits such as osteoporosis prevention," says Dr. Susan
 Fox, an internist specializing in women and hormone consultations, Beth Israel
 Medical Center and member of AMWA.  "Many women often discontinue their HRT
 regimen because of irregular bleeding without deriving the long-term benefits
 of HRTs.  However, today's HRT options can minimize some of these issues
 reducing the occurrence of breakthrough bleeding.  Women now can view
 menopause as an opportunity for new achievements."
 
     About Speaking with an Active Voice
     The Speaking with an Active Voice program embodies the spirit of
 ACTIVELLA(TM) by providing women with a great way to begin to take control of
 this phase of their lives.  The Speaking with an Active Voice grants sponsored
 by AMWA and Pharmacia celebrate and enhance the dreams and aspirations of
 American women.
 
     *     How to Apply -- Women can download the Speaking with an Active Voice
           grant application by logging on to http://www.activella.com or
           http://www.amwa-doc.org.  They can also request a copy of the
           application by calling toll-free 1-800-789-2535.
 
     *     Deadline for Applications -- Applications must be received by
           Monday, July 2, 2001.
 
     *     Who can Apply -- The grant program is open to all women ages 45 and
           55 who are beginning or continuing an established project in one of
           the following areas: education and lifelong learning, visual arts,
           literary arts, performing arts, business, medicine, civic and
           neighborhood programs, advancement of women's health and government.
           Women with interesting projects in other areas will also be
           considered.  Examples include but are not limited to: a woman who is
           starting a local Alzheimer's support group in honor of her mother; a
           woman who is decorating a fountain in a local park with artwork done
           by women with AIDS; and a woman who has left a corporate position to
           start a volunteer program.
 
     *     Award Announcement -- As many as 15 winners will be notified that
           they have won a grant by Wednesday, August 29, 2001.
 
     *     Additional Information -- For additional information about the
           Speaking with an Active Voice program, call Jennie Kim or Diana
           Scott, Manning Selvage and Lee, at 212-213-0909.
 
     About AMWA
     The American Medical Women's Association (AMWA) is an organization of
 10,000 women physicians and medical students dedicated to serving as the
 unique voice for women's health and the advancement of women in medicine.
 AMWA was founded in 1915, because women physicians were and are an
 under-represented minority.  AMWA works to empower women by providing
 physician and patient education about health topics that seriously impact the
 lives and health of women.
     AMWA believes medical decisions, including whether to use hormone
 replacement therapy, should be the decision of a woman and her health care
 provider.  AMWA does not endorse any specific hormone products or services.
 
     More About ACTIVELLA(TM)
     Speaking with an Active Voice embodies the spirit of ACTIVELLA(TM),
 encouraging women to make active life choices.  ACTIVELLA(TM) provides an
 important option for a generation of active, postmenopausal women.  It
 effectively relieves menopausal symptoms such as moderate to severe hot
 flashes, ACTIVELLA(TM) also minimizes irregular or unpredictable bleeding, a
 primary reason for discontinuation of HRT.  In a 12 month clinical study,
 85 percent of women taking ACTIVELLA(TM) reported no bleeding at three months.
 At twelve months, 97 percent of women experienced no bleeding.
     In addition, physician-prescribed ACTIVELLA(TM) addresses other concerns
 important to many women.  A recent attitudinal study of women ages 46-56 found
 that 77 percent of women believe that the source of the hormone in an HRT is
 important(2).  The raw material used to make the estrogen contained in
 ACTIVELLA(TM) is derived from plants and is chemically the same as the
 estrogen found in premenopausal women.
     ACTIVELLA(TM) is indicated in women with an intact uterus for the
 treatment of moderate to severe vasomotor symptoms, such as hot flashes and
 night sweats, associated with menopause, the treatments of vulvar and vaginal
 atrophy and for the prevention of postmenopausal osteoporosis.  ACTIVELLA(TM)
 should not be used in women with known or suspected pregnancy, breast cancer,
 estrogen-dependent neoplasia, active deep venous thrombosis, thromboembolic
 disorders or stroke, undiagnosed abnormal genital bleeding, liver dysfunction
 or disease or hypersensitivity to any of its ingredients.  Estrogen can
 increase the risk of cancer of the uterus.  Combining progestin with
 estrogen, as with ACTIVELLA(TM), significantly reduces this risk, but does not
 eliminate it completely.  A well-tolerated therapy, the most common adverse
 event reported in clinical trials with ACTIVELLA(TM) included breast
 tenderness/pain, headache, postmenopausal bleeding and nausea.
 
     About Pharmacia Corporation
     Pharmacia Corporation has a long history of developing and marketing
 products for women's health.  Currently the company offers a diverse portfolio
 of products for conditions that affect women, including contraception,
 menopause, breast cancer, overactive bladder and rheumatoid arthritis.
 Looking forward, the company remains committed to developing and investing in
 products that advance the health and enhance the lives of women.
     Pharmacia Corporation (NYSE:   PHA) is a leading global pharmaceutical
 company created through the merger of Pharmacia & Upjohn with Monsanto Company
 and its G.D. Searle unit.  Pharmacia has a broad product portfolio, a robust
 pipeline of new medicines and an annual investment of more than $2 billion in
 pharmaceutical research and development.
 
      (1)  North American Menopause Society website.  2001.
      (2)  The New World of HRT study, Patricia E. Breman, SRI Business
 Intelligence Center. 2000.
 
     Certain statements contained in this release, such as statements
 concerning the Company's anticipated financial results, current and new
 product performance, regulatory approvals, currency impact and other
 non-historical facts are "forward-looking statements" (as such term is defined
 in the Private Securities Litigation Reform Act of 1995).  Since these
 statements are based on factors that involve risks and uncertainties, actual
 results may differ materially from those expressed or implied by such
 forward-looking statements.  Such factors include, among others: management's
 ability to implement -- strategic initiatives; the Company's ability to
 successfully market new and existing products in new and existing domestic and
 international markets; the success of the Company's research and development
 activities and the speed with which regulatory authorizations and product
 roll-outs may be achieved; fluctuations in exchange rates; the effects of the
 Company's accounting policies and general changes in generally accepted
 accounting principles; the Company's exposure to product liability and other
 lawsuits and contingencies related to actual or alleged environmental
 contamination; domestic and foreign social, legal and political developments,
 especially those relating to health care reform and product liabilities;
 general economic and business conditions; the Company's ability to attract and
 retain current management and other employees of the Company; and other risks
 and factors detailed in the Company's Securities and Exchange Commission
 filings, including its Proxy Statement and Form 10-K for the year ended
 December 31, 1999.
 
     For more information about the Speaking with an Active Voice program, log
 onto http://www.activella.com or http://www.amwa-doc.org or call 800-789-2535.
 
     For more information on ACTIVELLA(TM), including full prescribing
 information, and Pharmacia Corporation, please contact us at 800-752-8779 or
 visit http://www.activella.com.  For physician and pharmacist information on
 ACTIVELLA(TM) please call 800-253-8600, ext. 3-8244.
 
     ACTIVELLA(TM) is a trademark of Pharmacia Corporation
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X45774337
 
 

SOURCE Pharmacia Corporation
    NEW YORK, April 25 /PRNewswire/ -- Actress and women's health activist
 Meredith Baxter today joins the American Medical Women's Association (AMWA)
 and Pharmacia Corporation, marketers of the hormone replacement therapy
 ACTIVELLA(TM) (estradiol/norethindrone acetate tablets), to launch the
 Speaking with an Active Voice program.  This nationwide grant program
 recognizes women who celebrate an active and meaningful life as they enter
 menopause.  The program provides seed funding to selected menopausal women who
 are enhancing their lives and the lives of those around them by embarking on
 new undertakings.
     "There are 4,000 baby boomer women entering menopause daily who expect to
 continue leading busy lives.  They aren't and don't want to be slowed down by
 symptoms associated with menopause," says Meredith Baxter, spokesperson for
 the Speaking with an Active Voice program.  "The Speaking with an Active Voice
 program embodies the spirit of ACTIVELLA(TM) by encouraging menopausal women
 to celebrate vibrant and energetic life choices."
     The nationwide program provides grants of at least $6,500 for as many as
 15 women ages 45-55 who are beginning or building upon a work venture, form of
 self-expression or community service. Women have until Monday, July 2, 2001 to
 apply for the grants.  Winners will be notified by Wednesday, August 29, 2001.
 
     This is Not Your Mother's Menopause
     Ensuring that women have the information and tools available to actively
 manage menopause is more important than ever.  Women of menopausal age make up
 the largest segment of the American population, with 41.75 million women over
 the age of 50(1).  Approximately 4,000 women enter menopause each day.  And in
 2000, three out of four (78.2 percent) women between the ages of 45 and 55
 worked outside of the home compared to two out of four (49.9 percent) women in
 1960.
     "Women don't want, and often can't afford, to slow down during menopause,"
 adds Baxter.  "Contraceptives liberated baby boomers during their
 child-bearing years.  Now as these women enter menopause, they expect to enjoy
 this vital time without skipping a beat.  With today's prescription hormone
 replacement therapies (HRTs), such as plant-derived ACTIVELLA(TM), women can
 expect effective relief from moderate to severe hot flashes and night sweats
 often associated with this chapter in their lives."
     "HRTs provide women with options to manage menopausal symptoms and can
 also offer long-term benefits such as osteoporosis prevention," says Dr. Susan
 Fox, an internist specializing in women and hormone consultations, Beth Israel
 Medical Center and member of AMWA.  "Many women often discontinue their HRT
 regimen because of irregular bleeding without deriving the long-term benefits
 of HRTs.  However, today's HRT options can minimize some of these issues
 reducing the occurrence of breakthrough bleeding.  Women now can view
 menopause as an opportunity for new achievements."
 
     About Speaking with an Active Voice
     The Speaking with an Active Voice program embodies the spirit of
 ACTIVELLA(TM) by providing women with a great way to begin to take control of
 this phase of their lives.  The Speaking with an Active Voice grants sponsored
 by AMWA and Pharmacia celebrate and enhance the dreams and aspirations of
 American women.
 
     *     How to Apply -- Women can download the Speaking with an Active Voice
           grant application by logging on to http://www.activella.com or
           http://www.amwa-doc.org.  They can also request a copy of the
           application by calling toll-free 1-800-789-2535.
 
     *     Deadline for Applications -- Applications must be received by
           Monday, July 2, 2001.
 
     *     Who can Apply -- The grant program is open to all women ages 45 and
           55 who are beginning or continuing an established project in one of
           the following areas: education and lifelong learning, visual arts,
           literary arts, performing arts, business, medicine, civic and
           neighborhood programs, advancement of women's health and government.
           Women with interesting projects in other areas will also be
           considered.  Examples include but are not limited to: a woman who is
           starting a local Alzheimer's support group in honor of her mother; a
           woman who is decorating a fountain in a local park with artwork done
           by women with AIDS; and a woman who has left a corporate position to
           start a volunteer program.
 
     *     Award Announcement -- As many as 15 winners will be notified that
           they have won a grant by Wednesday, August 29, 2001.
 
     *     Additional Information -- For additional information about the
           Speaking with an Active Voice program, call Jennie Kim or Diana
           Scott, Manning Selvage and Lee, at 212-213-0909.
 
     About AMWA
     The American Medical Women's Association (AMWA) is an organization of
 10,000 women physicians and medical students dedicated to serving as the
 unique voice for women's health and the advancement of women in medicine.
 AMWA was founded in 1915, because women physicians were and are an
 under-represented minority.  AMWA works to empower women by providing
 physician and patient education about health topics that seriously impact the
 lives and health of women.
     AMWA believes medical decisions, including whether to use hormone
 replacement therapy, should be the decision of a woman and her health care
 provider.  AMWA does not endorse any specific hormone products or services.
 
     More About ACTIVELLA(TM)
     Speaking with an Active Voice embodies the spirit of ACTIVELLA(TM),
 encouraging women to make active life choices.  ACTIVELLA(TM) provides an
 important option for a generation of active, postmenopausal women.  It
 effectively relieves menopausal symptoms such as moderate to severe hot
 flashes, ACTIVELLA(TM) also minimizes irregular or unpredictable bleeding, a
 primary reason for discontinuation of HRT.  In a 12 month clinical study,
 85 percent of women taking ACTIVELLA(TM) reported no bleeding at three months.
 At twelve months, 97 percent of women experienced no bleeding.
     In addition, physician-prescribed ACTIVELLA(TM) addresses other concerns
 important to many women.  A recent attitudinal study of women ages 46-56 found
 that 77 percent of women believe that the source of the hormone in an HRT is
 important(2).  The raw material used to make the estrogen contained in
 ACTIVELLA(TM) is derived from plants and is chemically the same as the
 estrogen found in premenopausal women.
     ACTIVELLA(TM) is indicated in women with an intact uterus for the
 treatment of moderate to severe vasomotor symptoms, such as hot flashes and
 night sweats, associated with menopause, the treatments of vulvar and vaginal
 atrophy and for the prevention of postmenopausal osteoporosis.  ACTIVELLA(TM)
 should not be used in women with known or suspected pregnancy, breast cancer,
 estrogen-dependent neoplasia, active deep venous thrombosis, thromboembolic
 disorders or stroke, undiagnosed abnormal genital bleeding, liver dysfunction
 or disease or hypersensitivity to any of its ingredients.  Estrogen can
 increase the risk of cancer of the uterus.  Combining progestin with
 estrogen, as with ACTIVELLA(TM), significantly reduces this risk, but does not
 eliminate it completely.  A well-tolerated therapy, the most common adverse
 event reported in clinical trials with ACTIVELLA(TM) included breast
 tenderness/pain, headache, postmenopausal bleeding and nausea.
 
     About Pharmacia Corporation
     Pharmacia Corporation has a long history of developing and marketing
 products for women's health.  Currently the company offers a diverse portfolio
 of products for conditions that affect women, including contraception,
 menopause, breast cancer, overactive bladder and rheumatoid arthritis.
 Looking forward, the company remains committed to developing and investing in
 products that advance the health and enhance the lives of women.
     Pharmacia Corporation (NYSE:   PHA) is a leading global pharmaceutical
 company created through the merger of Pharmacia & Upjohn with Monsanto Company
 and its G.D. Searle unit.  Pharmacia has a broad product portfolio, a robust
 pipeline of new medicines and an annual investment of more than $2 billion in
 pharmaceutical research and development.
 
      (1)  North American Menopause Society website.  2001.
      (2)  The New World of HRT study, Patricia E. Breman, SRI Business
 Intelligence Center. 2000.
 
     Certain statements contained in this release, such as statements
 concerning the Company's anticipated financial results, current and new
 product performance, regulatory approvals, currency impact and other
 non-historical facts are "forward-looking statements" (as such term is defined
 in the Private Securities Litigation Reform Act of 1995).  Since these
 statements are based on factors that involve risks and uncertainties, actual
 results may differ materially from those expressed or implied by such
 forward-looking statements.  Such factors include, among others: management's
 ability to implement -- strategic initiatives; the Company's ability to
 successfully market new and existing products in new and existing domestic and
 international markets; the success of the Company's research and development
 activities and the speed with which regulatory authorizations and product
 roll-outs may be achieved; fluctuations in exchange rates; the effects of the
 Company's accounting policies and general changes in generally accepted
 accounting principles; the Company's exposure to product liability and other
 lawsuits and contingencies related to actual or alleged environmental
 contamination; domestic and foreign social, legal and political developments,
 especially those relating to health care reform and product liabilities;
 general economic and business conditions; the Company's ability to attract and
 retain current management and other employees of the Company; and other risks
 and factors detailed in the Company's Securities and Exchange Commission
 filings, including its Proxy Statement and Form 10-K for the year ended
 December 31, 1999.
 
     For more information about the Speaking with an Active Voice program, log
 onto http://www.activella.com or http://www.amwa-doc.org or call 800-789-2535.
 
     For more information on ACTIVELLA(TM), including full prescribing
 information, and Pharmacia Corporation, please contact us at 800-752-8779 or
 visit http://www.activella.com.  For physician and pharmacist information on
 ACTIVELLA(TM) please call 800-253-8600, ext. 3-8244.
 
     ACTIVELLA(TM) is a trademark of Pharmacia Corporation
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X45774337
 
 SOURCE  Pharmacia Corporation